Alkermes Makes Board Appointment
Executive Summary
Alkermes plc., a global biopharma company focusing on the treatment of central nervous system diseases, has appointed Nancy Snyderman to its board of directors. Snyderman has more than 28 years of experience as a medical journalist, most recently at NBC News, where she was chief medical editor. Prior to her work in journalism, she was vice president of corporate communications at Johnson & Johnson. Snyderman is also a board certified otolaryngologist-head and neck surgeon, and a fellow of the American College of Surgeons.
You may also be interested in...
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Three New CMOs And CFOs Among This Week's Changes
Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.